Analyzing Acadia Pharmaceuticals Inc (ACAD) After Recent Trading Activity

Daniel Torres

Acadia Pharmaceuticals Inc’s recently made public that its Director Daly James M unloaded Company’s shares for reported $0.67 million on Nov 10 ’25. In the deal valued at $22.37 per share,30,000 shares were sold. As a result of this transaction, Daly James M now holds 4,041 shares worth roughly $96175.8.

Then, James M Daly bought 30,000 shares, generating $670,983 in total proceeds.

Before that, Schneyer Mark C. sold 3,498 shares. Acadia Pharmaceuticals Inc shares valued at $82,728 were divested by the EVP, CHIEF FINANCIAL OFFICER at a price of $23.65 per share. As a result of the transaction, Schneyer Mark C. now holds 43,447 shares, worth roughly $1.03 million.

Citigroup initiated its Acadia Pharmaceuticals Inc [ACAD] rating to a Buy in a research note published on October 21, 2025; the price target was $33. A number of analysts have revised their coverage, including Deutsche Bank’s analysts, who increased its forecast for the stock in late May from “a Hold” to “a Buy”. Deutsche Bank began covering ACAD with “Hold” recommendation on February 11, 2025. Guggenheim revised its rating on January 03, 2025. It rated ACAD as “a Neutral” which previously was an “a Buy”.

Price Performance Review of ACAD

On Tuesday, Acadia Pharmaceuticals Inc [NASDAQ:ACAD] saw its stock fall -0.87% to $23.8. Over the last five days, the stock has gained 0.34%. Acadia Pharmaceuticals Inc shares have risen nearly 39.84% since the year began. Nevertheless, the stocks have risen 29.70% over the past one year. While a 52-week high of $26.65 was reached on 08/28/25, a 52-week low of $13.40 was recorded on 04/09/25.

Levels Of Support And Resistance For ACAD Stock

The 24-hour chart illustrates a support level at 23.51, which if violated will result in even more drops to 23.22. On the upside, there is a resistance level at 24.08. A further resistance level may holdings at 24.37.

How much short interest is there in Acadia Pharmaceuticals Inc?

A steep rise in short interest was recorded in Acadia Pharmaceuticals Inc stocks on 2025-10-31, dropping by -0.9 million shares to a total of 8.51 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 9.41 million shares. There was a decline of -10.54%, which implies that there is a negative sentiment for the stock.

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.